What does Imunon, Inc. do?
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the…
What is Imunon, Inc.'s P/E and P/B ratio?
Imunon, Inc. has a P/E ratio of -0.3 and a P/B ratio of 2.09.
What is Imunon, Inc.'s debt-to-equity ratio?
Imunon, Inc. has a debt-to-equity ratio of 1.87.
How much does Imunon, Inc. owe compared with what it owns?
Imunon, Inc. owes $0.58 for every $1 it owns (balance sheet Mar 2026), which is moderate.
What is Imunon, Inc.'s Positivity rank?
Imunon, Inc. is ranked #3,925 of 6,774 companies globally and #1,833 of 4,000 in United States on PositoAI, with a Positivity Score of 20,091.
Does Imunon, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Imunon, Inc..
Where can I read the latest news about Imunon, Inc.?
Recent headlines about Imunon, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Imunon, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Imunon, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.